Results 31 to 40 of about 466,850 (166)

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights

open access: yesAmerican Journal of Hematology, EarlyView.
CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin   +3 more
wiley   +1 more source

Relapses, Comorbidities, and Predictors of Outcome in Anti‐GABAA Receptor Encephalitis

open access: yesAnnals of Neurology, EarlyView.
Objectives To characterize the magnetic resonance imaging (MRI) lesion dynamics, comorbidities, predictors of relapse, and outcomes in anti‐γ‐aminobutyric acid type A receptor (GABAAR) encephalitis, and assess the utility of LIM‐domain‐only‐protein 5 (LMO5) antibodies as tumor markers.
Claudia Papi   +33 more
wiley   +1 more source

Espiritualidad, religiosidad y enfermedad: una mirada desde mujeres con cáncer de mama

open access: yesAvances en Psicología Latinoamericana, 2015
The present investigation aims to explore the role of spirituality and religiosity in the way that women with breast cancer assume, signifiy and face their illness.
Yesica Milena Puentes Silva   +2 more
doaj   +1 more source

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]

open access: yes, 2012
The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco   +18 more
core   +4 more sources

Longitudinal Phenotypic Trajectories in GNAO1‐Related Disorders: Defining Disease Progression and Clinical Profiles

open access: yesAnnals of Neurology, EarlyView.
Objective Pathogenic variants in GNAO1 cause a spectrum of epilepsy, movement disorders, and developmental impairment. Clinical heterogeneity complicates prognosis and therapeutic development. We present the first longitudinal natural history study of GNAO1‐related disorders (GNAO1‐RD) to delineate phenotypic trajectories. Methods Sixty‐six individuals
Jana Domínguez‐Carral   +52 more
wiley   +1 more source

Cost-effectiveness of rapid-deployment aortic valve replacement over TAVI: a real-world retrospective cohort study

open access: yesJournal of Cardiothoracic Surgery
Background Aortic valve replacement (AVR) is the standard treatment for severe aortic stenosis. While transcatheter aortic valve implantation (TAVI) has recently been widely recommended, concerns remain regarding real-world long-term valve durability and
Kevin Maldonado-Cañón   +8 more
doaj   +1 more source

Biopreservation of hepatocytes: current concepts on hypothermic preservation, cryopreservation, and vitrification [PDF]

open access: yes, 2013
Isolated liver cells (primarily isolated hepatocytes) have found important applications in science and medicine over the past 40 years in a wide range of areas, including physiological studies, investigations on liver metabolism, organ preservation and ...
Balaban, Cecilia Lucía   +5 more
core  

Freedon study: Real‐life outcomes of cenobamate in different lines of treatment

open access: yesEpilepsia, EarlyView.
Abstract Objectives Cenobamate is an antiseizure medication (ASM) with proven effectiveness in individuals with highly refractory epilepsy. This study investigated the effectiveness and tolerability of cenobamate in different treatment lines and a less refractory setting. Methods This was a multicenter, retrospective, observational study.
Vicente Villanueva   +50 more
wiley   +1 more source

Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment [PDF]

open access: yes, 2014
The aim of this study was to evaluate the effect of strontium ranelate (SrR) on bone mineral density (BMD) and boneturnover markers after 1 year of treatment.
Brance, María Lorena   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy